Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 29, 2004
- New NHI Prices Gazetted on March 5
March 22, 2004
- BUSINESS NEWS IN BRIEF
March 22, 2004
- Japan CRO Association Holds 10th Anniversary Symposium
March 22, 2004
- Novartis Has 58 Products in PII, PIII in US: CEO Ebeling
March 22, 2004
- Meet the Leaders (31)
March 22, 2004
- Banyu to "Seriously Go After the Japanese Market": Mr Hirate
March 22, 2004
- Annual Business Results
March 22, 2004
- Aiming to Be a "Global Mega-player" via Merger: Dr Aoki of Fujisawa
March 22, 2004
- WORLD NEWS IN BREIF
March 22, 2004
- Eisai Seeks Efficiency, Not Scale: Mr Naito
March 22, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 22, 2004
- Pfizer Japan Aims to Boost MR Productivity by 50% in 5 Years: Mr Bootes
March 22, 2004
- OTC NEWS IN BRIEF
March 22, 2004
- BULLETIN
March 22, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 22, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 22, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 22, 2004
- REGULATORY NEWS IN BRIEF
March 22, 2004
- Impact of NHI Price Revisions Ranges from 3% to 7%
March 22, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…